What is the 13F Pro Quality Score for SGMO?

13F Pro ranks SANGAMO THERAPEUTICS, INC (SGMO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SGMO's current score at https://13fpro.ai/research/SGMO (free sign-up required for the full ranking).

Where does 13F Pro source SGMO data?

All SANGAMO THERAPEUTICS, INC fundamentals and ownership data come directly from SEC EDGAR. SANGAMO THERAPEUTICS, INC files with the SEC under CIK 1001233. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SGMO in?

SANGAMO THERAPEUTICS, INC (SGMO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SGMO research updated on 13F Pro?

SGMO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SANGAMO THERAPEUTICS, INC(SGMO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1001233 SGMO stock profile & AI dashboard →

13F Pro Quality Score

8.8/100

Rank #2,821 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

0.5/100

Profitability

3.6/100

Balance Sheet

0.2/100

Earnings Quality

30.0/100

Free Cash Flow

4.0/100

Institutional Flow

88.9/100

Revenue Scale

6.5/100

Dilution Risk

8.1/100

SGMO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SANGAMO THERAPEUTICS, INC (SGMO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SGMO at 8.8/100 on a 32-signal composite quality model, placing it at rank #2,821 of 2,879 stocks — the bottom half of the AI-ranked universe. SGMO scores in the top quartile across institutional flow (88.9). Areas of concern include balance sheet strength (0.2) and revenue growth (0.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SANGAMO THERAPEUTICS, INC reports quarterly revenue of $1.4M, net income of $-31.0M, free cash flow of $-19.3M. Top institutional holders of SGMO by reported 13-F value include ARMISTICE CAPITAL,, VANGUARD CAPITAL MANAGEMENT, TWO SIGMA INVESTMENTS,, based on the most recent SEC filings. SGMO trades on the Nasdaq exchange and files with the SEC under CIK 1001233. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SGMO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SANGAMO THERAPEUTICS, INC directly from SEC EDGAR. SANGAMO THERAPEUTICS, INC's 13F Pro composite quality score has ranged between 6 and 45 since 2021, currently 8.8 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about SANGAMO THERAPEUTICS, INC

Quirks, history, and lore behind SGMO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Revenue is modest — largely from collaborations and licensing deals rather than commercial products — typical of a clinical-stage genomic medicine firm burning cash to fund R&D.
3
The History
Founded in the late 1990s, it was an early pioneer in zinc finger nuclease (ZFN) technology — a molecular scissors approach to editing DNA that predates the CRISPR craze by years.
4
The Secret
Its platform can insert, correct, or silence genes with high precision, and it has parlayed that into big-pharma partnerships targeting diseases from hemophilia to HIV.
5
The Lore
It struck high-profile collaborations with Pfizer and Sanofi, and its approach to in vivo gene editing — editing genes inside the living body rather than in a dish — has made it a closely watched name in genomic medicine circles.
6
The Giveaway
The original zinc finger genome editing specialist, ticker SGMO, is betting its future on cell therapies and in vivo gene correction — one precise molecular snip at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$1.4M

Net Income

Q1 2026

$-31.0M

Free Cash Flow

Q1 2026

$-19.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-31.6% YoY

$39.6MFY 2025

FY21 $110.7MFY23 $176.2MFY24 $57.8MFY25 $39.6M

Net Income

-25.5% YoY

$-122.9MFY 2025

FY21 $-178.3MFY23 $-257.8MFY24 $-97.9MFY25 $-122.9M

Operating Income

-16.6% YoY

$-121.2MFY 2025

FY21 $-183.3MFY23 $-274.0MFY24 $-104.0MFY25 $-121.2M

EPS (Diluted)

+10.2% YoY

$-0.44FY 2025

FY21 $-1.23FY23 $-1.48FY24 $-0.49FY25 $-0.44

Total Assets

-41.2% YoY

$59.7MFY 2025

FY21 $721.9MFY23 $165.3MFY24 $101.6MFY25 $59.7M

Op. Cash Flow

-44.8% YoY

$-97.2MFY 2025

FY21 $-233.3MFY23 $-224.8MFY24 $-67.1MFY25 $-97.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2018
Revenue	$39.6M -31.6%	$57.8M -67.2%	$176.2M +59.2%	$110.7M -6.3%	$118.2M +40.0%	$84.5M
Net Income	$-122.9M -25.5%	$-97.9M +62.0%	$-257.8M -44.6%	$-178.3M -47.4%	$-121.0M -77.1%	$-68.3M
Operating Income	$-121.2M -16.6%	$-104.0M +62.1%	$-274.0M -49.5%	$-183.3M -41.5%	$-129.6M -67.9%	$-77.2M
EPS (Diluted)	$-0.44 +10.2%	$-0.49 +66.9%	$-1.48 -20.3%	$-1.23 -36.7%	$-0.90	—
Total Assets	$59.7M -41.2%	$101.6M -38.5%	$165.3M -77.1%	$721.9M -23.1%	$938.5M +59.0%	$590.4M
Operating Cash Flow	$-97.2M -44.8%	$-67.1M +70.1%	$-224.8M +3.6%	$-233.3M -237.3%	$169.9M +364.8%	$36.5M

AI Insight: SGMO Financial Trends

Sangamo has deteriorated sharply: revenue collapsed to $1M in Q1 2026, equity turned negative, and operating losses persisted across all eight quarters.

• Revenue averaged $12M over eight quarters; Q3 2024's $49M peak was isolated. Latest quarter Q1 2026 fell to $1M.

• Operating income negative in 6 of 8 quarters. Q1 2026 operating loss of $32M matches the run rate of prior quarters.

• Equity eroded from $24M (Q2 2024) to −$19M (Q1 2026). Company now technically insolvent on a book basis.

⚠ Operating cash flow negative every quarter; Q1 2026 −$19M. No path to cash generation visible.

⚠ No debt reported; equity collapse suggests cash burn is primary solvency risk. Runway unclear without financing.

AI Insight: SGMO Ratio Trends

Sangamo shifted from profitable operations in Q3 2024 to severe losses by Q2 2025, with operating margin collapsing 119 percentage points.

• Operating margin fell from 21.5% in Q3 2024 to -97.5% in Q2 2025, signaling a dramatic operational deterioration.

• Net profit margin swung from positive 21.6% in Q3 2024 to -109.2% in Q2 2025, indicating core profitability collapse.

• Return on assets fell from 38.4% in Q3 2024 to -82.0% in Q2 2025, showing severe asset value destruction.

⚠ Data gaps from Q1 2025 onward obscure full picture; only Q2 2025 profitability metrics available. Monitor upcoming filings for recovery signs.

⚠ Q4 2024 showed ROA of -92.1%, suggesting losses began before Q2 2025. Trajectory and cause require clarification.

Get alerted when SGMO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SANGAMO THERAPEUTICS, INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SGMO

ARMISTICE CAPITAL, LLC
$10.0M40,400,067 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.1M12,704,408 sh
TWO SIGMA INVESTMENTS, LP
$1.5M6,270,441 sh
BALYASNY ASSET MANAGEMENT L.P.
$1.3M5,288,097 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.1M4,570,862 sh
BlackRock, Inc.
$1.1M4,547,848 sh
RENAISSANCE TECHNOLOGIES LLC
$947.3K3,836,665 sh
UBS Group AG
$635.0K2,570,992 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$580.8K2,352,360 sh
VANGUARD FIDUCIARY TRUST CO
$570.6K2,310,297 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$10.0M	40,400,067
VANGUARD CAPITAL MANAGEMENT LLC	$3.1M	12,704,408
TWO SIGMA INVESTMENTS, LP	$1.5M	6,270,441
BALYASNY ASSET MANAGEMENT L.P.	$1.3M	5,288,097
GEODE CAPITAL MANAGEMENT, LLC	$1.1M	4,570,862
BlackRock, Inc.	$1.1M	4,547,848
RENAISSANCE TECHNOLOGIES LLC	$947.3K	3,836,665
UBS Group AG	$635.0K	2,570,992
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$580.8K	2,352,360
VANGUARD FIDUCIARY TRUST CO	$570.6K	2,310,297

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SGMO on your watchlist

Track score changes the day SANGAMO THERAPEUTICS, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SGMO a good stock to buy?

13F Pro's AI-powered analysis of SANGAMO THERAPEUTICS, INC (SGMO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SGMO are available on the SGMO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SGMO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SGMO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SANGAMO THERAPEUTICS, INC's investment landscape.